Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transcenta HoldingHKSE:06628 +7.06%40 Quick Ratio is 0.19 as of Dec. 2025, which is 90% below its 10-year median of 1.88. GuruFocus rates HKSE:06628 with a GF Score™ of 40/100 and a GF Value™ of HK$0.29 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,409 Biotechnology companies, Transcenta Holding ranks worse than 94.39% on this metric.
Transcenta Holding (HKSE:06628) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Transcenta Holding Quick Ratio Related Terms
Transcenta Holding Quick Ratio Historical Data
* Premium members only.
The historical data trend for Transcenta Holding's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06628 vs VRTX, REGN, MRNA: Quick Ratio Comparison
For the Biotechnology subindustry, Transcenta Holding's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transcenta Holding Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transcenta Holding's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Transcenta Holding's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Transcenta Holding's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transcenta Holding (HKSE:06628) has a Quick Ratio of 0.19 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Transcenta Holding and its competitors. This is 90% below median its historical median of 1.88. Over the past decade, Transcenta Holding's Quick Ratio has ranged from 0.19 to 4.54. According to the industry distribution chart, Transcenta Holding ranks #1330 out of 1409 companies in the Biotechnology industry, placing it in the top 94.4%.
Is Transcenta Holding's Quick Ratio too high?
Transcenta Holding's current Quick Ratio of 0.19 is 90% below median its 10-year median of 1.88. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 4.54. The Biotechnology industry median Quick Ratio is 3.60. Transcenta Holding's value of 0.19 is 94.7% below this industry median. Based on the distribution chart, Transcenta Holding ranks #1330 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transcenta Holding has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transcenta Holding's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transcenta Holding ranks #1330 out of 1409 companies for Quick Ratio. This places Transcenta Holding in the lower half of its industry. The industry median Quick Ratio is 3.60. Transcenta Holding's value of 0.19 is 94.7% below this benchmark. Historically, Transcenta Holding's own Quick Ratio has ranged from 0.19 to 4.54 over the past decade. While the company's 10-year median is 1.88 vs. the industry median of 3.60, Transcenta Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transcenta Holding's current Quick Ratio of 0.19 is 94.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Transcenta Holding and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transcenta Holding's current Quick Ratio is 0.19, which is 90% below median its own 10-year median of 1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transcenta Holding stock overvalued right now?
Based on GuruFocus' analysis, Transcenta Holding (HKSE:06628) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.91 — trading 213.8% above its estimated fair value. The current Quick Ratio is 0.19, which is 90% below median its 10-year median of 1.88 and 94.7% below the Biotechnology industry median of 3.60. Transcenta Holding's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Transcenta Holding (HKSE:06628), the current Quick Ratio is 0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transcenta Holding (HKSE:06628) Overvalued in 2026?
Based on GuruFocus' analysis, Transcenta Holding stock appears to be overvalued.
The current stock price of HK$0.91 is trading 213.8% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Transcenta Holding to be Significantly Overvalued.
Key valuation signals for HKSE:06628:
Quick Ratio: 0.19 (90% below median its 10-year median of 1.88)
GF Value™: HK$0.29 vs. price of HK$0.91 (213.8% above fair value)
Industry Position: 94.7% below the Biotechnology median (#1330 of 1409)
No single metric tells the full story. See the HKSE:06628 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
40GF Score
Get the complete analysis for HKSE:06628
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06628 has been successfully added to your 
